INFECTIOUS DISEASES AND IMMUNIZATION: Edited by Robert FrenckCOVID-19 vaccine development: a pediatric perspectiveKamidani, Satoshia; Rostad, Christina A.a,b; Anderson, Evan J.a,b,cAuthor Information aDepartment of Pediatrics, Emory University School of Medicine bCenter for Childhood Infections and Vaccines (CCIV), Children's Healthcare of Atlanta cDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA Correspondence to Evan J. Anderson, MD, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322, USA. Tel: +1 404 727 1746; e-mail: [email protected] Current Opinion in Pediatrics: February 2021 - Volume 33 - Issue 1 - p 144-151 doi: 10.1097/MOP.0000000000000978 Buy Metrics Abstract Purpose of review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes coronavirus disease 2019 (COVID-19), has caused substantial morbidity and mortality. Operation Warp Speed aims to accelerate the development of a safe and effective vaccine by early 2021. Multiple vaccine candidates with reassuring safety and efficacy profiles have advanced to phase 3 clinical trials in adults. The purpose of this review is to describe the burden of COVID-19 in children, to update pediatricians about adult COVID-19 vaccine clinical trials, to discuss the importance of COVID-19 vaccine trials in children and to instill confidence in the established vaccine development and licensure processes. Recent findings Children of all ages are at risk for SARS-CoV-2 infection and severe disease manifestations. Children are also susceptible to downstream effects of COVID-19, including social isolation and interruption in education. Developing a pediatric COVID-19 vaccine could prevent disease, mitigate downstream effects and enable children to re-engage in their world. Summary Children could benefit both directly and indirectly from vaccination. In light of the safety and immunogenicity results from recent adult COVID-19 vaccine clinical trials, children should have the opportunity to be included in clinical trials in parallel to ongoing adult phase 3 clinical trials in a manner that is careful, methodical and transparent. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.